News
02-18-2011, 02:41 AM
Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.
More... (http://www.news-medical.net/news/20110218/Cyclacels-CYC065-CDK-inhibitor-demonstrates-potential-against-breast-cancer-resistant-to-trastuzumab.aspx)
More... (http://www.news-medical.net/news/20110218/Cyclacels-CYC065-CDK-inhibitor-demonstrates-potential-against-breast-cancer-resistant-to-trastuzumab.aspx)